During the past decade, Indiana Univ Melvin & Bren Simon Cancer Center conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 5 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Indiana Univ Melvin & Bren Simon Cancer Center" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Aptose Biosciences Inc." with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Clovis Oncology, Inc." with 1 trials sponsored and "Indiana University" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Indiana Univ Melvin & Bren Simon Cancer Center" #1 collaborator was "Council for the Advancement of Nursing Science (CANS)" with 1 trials as a collaborator, "Foundation Medicine" with 1 trials as a collaborator, "Indiana Center for Vascular Biology & Medicine (ICVBM)" with 1 trials as a collaborator, "Indiana University School of Medicine" with 1 trials as a collaborator and "Loxo Oncology, Inc." with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Indiana Univ Melvin & Bren Simon Cancer Center" are "Acute Myeloid Leukemia" (1 trials), "Advanced Solid Tumor" (1 trials), "BRCA 1 Gene Mutation" (1 trials), "BRCA 2 Gene Mutation" (1 trials) and "Bladder Cancer" (1 trials). Many other conditions were trialed in "Indiana Univ Melvin & Bren Simon Cancer Center" in a lesser frequency.

Most popular intervention types in "Indiana Univ Melvin & Bren Simon Cancer Center" are "Drug" (6 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (2 trials), "Cetuximab" (2 trials), "Axon Flares" (1 trials), "Axon Reflexes" (1 trials) and "CC-5013" (1 trials). Other intervention names were less common.

The vast majority of trials in "Indiana Univ Melvin & Bren Simon Cancer Center" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Indiana Univ Melvin & Bren Simon Cancer Center". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Indiana Univ Melvin & Bren Simon Cancer Center, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Indiana Univ Melvin & Bren Simon Cancer Center, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".